The role of HIV-infection in the development risk factors of cardiovascular diseases in naive HIV-infected patients and HIV-infected patients on antiretroviral therapy

Cover Page

Cite item

Full Text

Abstract

Cardiovascular diseases are one of the main reasons of death in the modern world. Risk factor conception is emphasized in theirs prophylaxis. Nowadays besides risk factors mark out so called «special» population groups in which prophylactic actions school be more aggressive because of high cardiovascular risk. One of such groups is HIV-infected patients. It well known that among them the prevalence of traditional and «new» risk factors is much higher. At the same time in spite of the fact that there are a lot of trials it is lack of evidence about cardiovascular risk factors in HIV-infected patients with the saved immune system function as in «naive», so in antiretroviral treated patients. The aim of our investigation was to evaluate range of express traditional and «new» risk factors in «naive» and antiretroviral treated HIV-infected patients with the saved immune system function.

About the authors

I. I Chukayeva

Pirogov Russian National Research Medical University, Department of Outpatient Therapy № 2 of Medical Faculty, Moscow

д-р мед. наук, проф., зав. каф. поликлин. терапии №2 лечебного факультета

I. V Komarova

Pirogov Russian National Research Medical University, Department of Outpatient Therapy № 2 of Medical Faculty, Moscow

Email: irka.komarova@gmail.com
ассистент каф. поликлин. терапии №2 лечебного факультета

A. V Kravchenko

Central Research Institute of Epidemiology, Moscow

Email: alexey-kravtchenko@yandex.ru
д-р мед. наук, проф. ФБУН ЦНИИЭ

T. E Kushakova

Central Research Institute of Epidemiology, Moscow

Email: tatyanaq@mail.ru
аспирантка ФБУН ЦНИИЭ

References

  1. Мировой отчет по неинфекционным заболеваниям. ВОЗ. Женева, 2010.
  2. Obel N, Thomsen H.F, Kronborg G et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population - based cohort study. Clin Infect Dis 2007; 44: 1625-31.
  3. Triant V.A. HIV and Cardiovascular Disease. HIV/AIDS Annual Up - date, 2010.
  4. Saves M, Chene G, Ducimetiere P et al. French WHO MONICA Project and the APROCO (ANRS EP11) Study Group. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003; 37: 292-8.
  5. El-Sadr W.M, Mullin C.M, Carr A et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral - naive cohort. HIV Med 2005; 6 (2): 114-21.
  6. Iffen T.S, Efobi H, Usoro C.A.O et al. Lipid Profile of HIV-Positive Patients Attending University of Calabar Teaching Hospital, Calabar - Nigeria. World J Med Sci 2010; 5 (4): 89-93.
  7. Oko F, Naito T, Oike M et al. Correlation between HIV disease and lipid metabolism in antiretroviral - naive HIV - infected patients in Japan. J Infect Chemotherapy 2012; 18 (1): 17-21.
  8. Grunfeld C, Kotler D.P, Hamadeh R et al. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989; 86: 27-31.
  9. Daniyam C.A, Iroezindu M.O. Lipid Profile of Anti-Retroviral Treatment-Naive HIV-Infected Patients in Jos, Nigeria. Ann Med Health Sci Res 2013; 3 (1): 26-30.
  10. Noor M.A, Lo J.C, Mulligan K et al. Metabolic effects of indinavir in healthy HIV-seronegative men. Aids 2001; 15: 11-8.
  11. Mildvan D, Machado S.G, Wilets I et al. Endogenous interferon and triglyceride concentrations to assess response to zidovudine in AIDS and advanced AIDS-related complex. Lancet 1992; 339: 453-6.
  12. Mulligan K, Grunfeld C, Tai V.W et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000; 23: 35-43.
  13. Sullivan A.K, Feher M.D, Nelson M.R et al. Marked hypertriglyceridaemia associated with ritonavir therapy. AIDS 1998; 12: 1393-4.
  14. Segerer S, Bogner J.R, Walli R et al. Hyperlipidemia under treatment with proteinase inhibitors. Infection 1999; 27: 77-81.
  15. Periard D, Telenti A, Sudre P et al. Atherogenic dyslipidemia in HIVinfected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999; 100: 700-5.
  16. Bitnun A, Sochett E, Dick P.T. Insulin Sensitivity and b-Cell Function in Protease Inhibitor-Treated and Naive Human Immunodeficiency Virus-Infected Children. JCEM 2005; 90 (1): 168-74.
  17. Murata H, Hruz P.W, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000; 275: 20251-4.
  18. Meininger G, Hadigan C, Rietschel P et al. Body - composition measurements as predictors of glucose and insulin abnormalities in HIV- positive men. Am J Clin Nutr 2002; 76: 460-5.
  19. Hadigan C, Miller K, Corcoran C et al. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus - infected women. J Clin Endocrinol Metab 1999; 84: 1932-7.
  20. El-Sadr W.M, Mullin C.M, Carr A et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral - naive cohort. HIV Med 2005; 6 (2): 114-21.
  21. Baker J, Ayenew W, Quick H et al. High - density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection. J Infect Dis 2010; 201: 285-92.
  22. Jong E, Louw S, Meijers J.C et al. The hemostatic balance in HIV-infected patients with and without antiretroviral therapy: partial restoration with antiretroviral therapy. AIDS Patient Care STDS 2009; 23: 1001-7.
  23. Arildsen H, Sorensen K.E, Ingerslev J.M et al. Endothelial dysfunction, increased inflammation, and activated coagulation in HIV-infected patients improve after initiation of highly active antiretroviral therapy. HIV Med 2013; 14 (1): 1-9.
  24. Bernardino J, Merino J, Serrano L et al. Longitudinal comparison of inflammatory, coagulation and metabolic biomarkers in patients who start ART versus patients who remain ART-naive. Abstracts of the Eleventh International Congress on Drug Therapy in HIV Infection. J Int AIDS Soc 2012; 15 (4): 182-4.
  25. Ledwaba L, Tavel A.J, Paul Khabo P et al. Pre-ART Levels of Inflammation and Coagulation Markers Are Strong Predictors of Death in a South African Cohort with Advanced HIV Disease PLoS One 2012; 7 (3): e24243.
  26. Abdollahi A, Shoar T.S. Hyperhomocysteinemia in HIV-Infected Individuals: Correlation of a Frequent Prothrombotic Factor with CD4+ Cell Count. Oman Med J 2012; 27 (3): 224-7.
  27. Melenko S.R, Sorokhan V.D. Von Willebrand factor as a marker of endothelium disfunction on patints with HIV/AIDS. Материалы IV международной научно - практической конференции «Образование и наука». София: Бял ГРАД-БГ, 2010; 16: 56-9.
  28. Miller T.L, Borkowsky W, Di Meglio L.A et al. Metabolic Abnormalities and Viral Replication is Associated with Biomarkers of Vascular Dysfunction in HIV-Infected Children. HIV Med 2012; 13 (5): 264-75.
  29. Dolan S.E, Hadigan C, Killilea K.M et al. Increased Cardiovascular Disease Risk Indices in HIV-Infected Women. J Acquir Immune Defic Syndr 2005; 39: 44-54.
  30. Arildsen H, Sorensen K.E, Ingerslev J.M et al. Endothelial dysfunction, increased inflammation, and activated coagulation in HIV-infected patients improve after initiation of highly active antiretroviral therapy. HIV Med 2013; 14 (1): 1-9.
  31. Calmy A, Gayet-Ageron A, Montecucco F. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. 2009; AIDS 23 (8): 929-39.
  32. Phillips A.N, Carr A, Neuhaus J еt al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther 2008; 13: 177-87.
  33. Fisac C, Fumero E, Crespo M et al. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS 2005; 19: 917-25.
  34. Lane B.R, Markovitz D.M, Woodford N.L et al. TNF-alpha inhibits HIV-1 replication in peripheral blood monocytes and alveolar macrophages by inducing the production of RANTES and decreasing C-C chemokine receptor 5 (CCR5) expression. J Immunol 1999; 163 (7): 3653-61.
  35. Jeong S.J, Chin B.S, Chae Y.T et al. Serum retinol - binding protein-4 levels are increased in HIV-infected subjects with metabolic syndrome receiving highly active antiretroviral therapy. Yonsei Med J 2012; 53 (6): 1211-5.

Copyright (c) 2014 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies